UTHR Rule 144 Notice: Martine Rothblatt proposes 4,000-share sale
Rhea-AI Filing Summary
UNITED THERAPEUTICS (UTHR) reported a Rule 144 notice disclosing a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,807,320. The filing shows these shares were acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, and payment was made by exercising vested options with shares used for payment. The issuer has 45,230,000 shares outstanding, so the single proposed block equals roughly 0.009% of outstanding stock. The filing also itemizes prior open-market sales by the same person totaling 80,000 shares over the past three months, generating multi‑million dollar proceeds on multiple dates.
Positive
- Transparent disclosure of a planned insider sale under Rule 144, specifying broker, acquisition date, and payment method
- Detailed history of past open-market sales (totaling 80,000 shares) provides context for recent dispositions
Negative
- Insider selling activity continued over recent months (80,000 shares sold), which some investors may view unfavorably despite immaterial size
- No information in this filing about remaining insider holdings after the recent sales, limiting assessment of post-sale ownership concentration
Insights
Insider disclosed routine sales; size is immaterial to float.
The notice shows a planned sale of 4,000 common shares valued at $1,807,320, acquired in 2016-03-15 via executive deferred compensation and option exercise. With 45,230,000 shares outstanding, the single proposed sale is a very small fraction of the company’s share count.
Recent activity lists 80,000 shares sold in the last three months, producing multi‑million dollar proceeds across many dates; this trading history is transparent and consistent with scheduled or opportunistic dispositions. Monitor quarterly filings for any change in insider ownership trends over the next 3 months.
Disclosure follows Rule 144 mechanics and includes source and payment details.
The filing specifies the acquisition date, nature of acquisition (executive deferred compensation), and that payment involved exercised vested options paid in common shares, which clarifies transfer basis for compliance purposes. The filer also affirms absence of undisclosed material nonpublic information as required by the form.
Investors interested in insider intentions should watch proxy and Form 4 disclosures and any amended 144 filings within 30 days for updates to planned sale timing.